News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

PledPharma strengthens the management team with a Vice President Product Strategy and Development

June 29, 2017

PledPharma AB
Investor News

PledPharma strengthens the management team with a Vice President Product
Strategy and Development

Stockholm, 2017-06-29 08:00 CEST (GLOBE NEWSWIRE) -- 
PledPharma announces today that Christian Sonesson has been appointed to the
newly created position as Vice President Product Strategy and Development. He
will lead the continued development program of the company's drug candidate
PledOx ®, as well as being responsible for the design of pricing strategies,
initial market positioning and expansion of potential indications. 

"We are pleased to welcome Christian Sonesson to PledPharma. The appointment is
an important part of the work to further strengthen the organization prior to
the completion of the remaining clinical studies and the parallel preparations
for a successful commercialization of the company's most advanced project,
PledOx®, a potentially new drug for preventing nerve damage caused by
chemotherapy treatment", said PledPharmas CEO, Nicklas Westerholm. 

Christian Sonesson holds an Executive MBA from the Stockholm School of
Economics and a PhD in Biostatistics from the University of Gothenburg. He has
been 13 years at AstraZeneca and most recently as Director Global Products,
where he was responsible for overall project strategies and the delivery of
comprehensive Phase III clinical trials. Christian also has extensive
experience of interactions with regulatory authorities and from successful
registrations of new drug candidates in different regions. 

Christian is joining PledPharma on August 15, 2017.

For more information, please contact:

Nicklas Westerholm, CEO, phone: +46 73 354 20 62

Michaela Gertz, CFO, phone: +46 709 26 17 75

About PledPharma

PledPharma develops new drugs that protect the body against oxidative stress –
a potentially debilitating and sometimes life-threatening condition that can be
caused by chemotherapy treatment and following acetaminophen (paracetamol)
overdose. The company's most advanced project PledOx® is being developed to
reduce nerve damage associated with chemotherapy. A phase IIb study has been
conducted and will serve as the basis for the continued development. The drug
candidate Aladote® is being developed to reduce the risk of acute liver failure
associated with acetaminophen poisoning. PledPharma (STO: PLED) is listed on
Nasdaq First North. Erik Penser Bank is the company’s Certified Adviser (tel
+46 8 463 80 00). For more information, see



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10